Hindustan Bio Science last traded at ₹7.61 (2026-10-13). Over the past month the stock moved -3.9%, three months the stock moved -10.3%, year the stock moved -6.9%. Its closing range over 52 weeks is ₹5.13 – ₹9.43, with the latest close 19.3% below the high.
Closing prices up to 2026-10-13.
Incorporated in 2000, Hindustan Biosciences Ltd manufactures & sells pharmaceutical products.[1]
Business Overview:[1][2] HBSL previously sourced bulk drugs (APIs) and drug intermediates and holds an import license from GEAC for Recombinant Human Erythropoietin, following clinical trials. It now manufactures and markets a wide range of premium finished dosage forms in pharmaceutical and biotechnology segments.
In the latest quarter (Jun 2026), Hindustan Bio Science reported sales of ₹0.00 crore (-100.0%) and net profit of ₹-0.11 crore (-1200.0%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 0.00 | -0.11 | – | -0.11 | -0.11 |
| Mar 2026 | 0.00 | -0.11 | – | -0.12 | -0.12 |
| Dec 2025 | 0.38 | 0.07 | 18.42 | 0.08 | 0.08 |
| Sep 2025 | 0.00 | -0.06 | – | -0.06 | -0.06 |
| Jun 2025 | 0.32 | 0.00 | 0.00 | 0.01 | 0.01 |
| Mar 2025 | 0.38 | 0.10 | 26.32 | 0.11 | 0.11 |
| Dec 2024 | 0.00 | -0.04 | – | -0.04 | -0.04 |
| Sep 2024 | 0.41 | 0.07 | 17.07 | 0.08 | 0.08 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +28.1% | -100.0% | -2.6% | -22.0% | -100.0% | – | -100.0% | -100.0% |
| Operating profit growth | +16.7% | -166.7% | +150.0% | -100.0% | -185.7% | – | -210.0% | – |
| Net profit growth | +14.3% | -157.1% | +175.0% | -87.5% | -175.0% | – | -209.1% | -1200.0% |
| EPS growth | +14.3% | -157.1% | +175.0% | -87.5% | -175.0% | – | -209.1% | -1200.0% |
| OPM % | 17.1% | – | 26.3% | 0.0% | – | 18.4% | – | – |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
In the latest year (Mar 2026), Hindustan Bio Science reported sales of ₹0.74 crore (-8.6%) and net profit of ₹-0.08 crore (-180.0%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 0.74 | -0.06 | -8.11 | -0.08 | -0.08 |
| Mar 2025 | 0.81 | 0.10 | 12.35 | 0.10 | 0.10 |
| Mar 2024 | 1.05 | 0.06 | 5.71 | 0.06 | 0.06 |
| Mar 2023 | 0.92 | -0.03 | -3.26 | -0.04 | -0.04 |
| Mar 2022 | 0.43 | -0.51 | -118.60 | -0.52 | -0.51 |
| Mar 2021 | 1.03 | -0.94 | -91.26 | -0.94 | -0.92 |
| Mar 2020 | 1.94 | 0.14 | 7.22 | 0.08 | 0.08 |
| Mar 2019 | 3.56 | 0.13 | 3.65 | 0.11 | 0.11 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +245.6% | -45.5% | -46.9% | -58.3% | +114.0% | +14.1% | -22.9% | -8.6% |
| Operating profit growth | – | +7.7% | -771.4% | – | – | – | +66.7% | -160.0% |
| Net profit growth | – | -27.3% | -1275.0% | – | – | – | +66.7% | -180.0% |
| EPS growth | – | -27.3% | -1250.0% | – | – | – | +66.7% | -180.0% |
| OPM % | 3.7% | 7.2% | -91.3% | -118.6% | -3.3% | 5.7% | 12.4% | -8.1% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
No AI analysis generated yet for Hindustan Bio Science.
Get Free AI Stock Analysis FREE →No recent news available for Hindustan Bio Science.
Hindustan Bio Science shares were last quoted at ₹7.61 (+2.1% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
Hindustan Bio Science has a price-to-earnings (P/E) ratio of -36.10 and a price-to-book (P/B) ratio of 10.31. The industry P/E is 29.79.
The 52-week high of Hindustan Bio Science is ₹9.92 and the 52-week low is ₹5.00.
The market capitalisation of Hindustan Bio Science is about ₹7.40 crore.
In the latest quarter (Jun 2026), Hindustan Bio Science reported sales of ₹0.00 crore (-100.0%) and net profit of ₹-0.11 crore (-1200.0%), compared with the same quarter last year.
This page is for information and is not investment advice. As per the data shown here, Hindustan Bio Science has a 3-year ROE of 3.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
Promoters hold about 12.19% of Hindustan Bio Science.
Hindustan Bio Science belongs to the Pharmaceuticals & Drugs sector.